Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis
Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_82
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Wiley